PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Given Average Recommendation of “Hold” by Analysts

Shares of PROCEPT BioRobotics Corporation (NASDAQ:PRCT) have been given a consensus recommendation of “Hold” by the sixteen brokerages that are presently covering the firm, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation, ten have given a hold recommendation, three have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $28.00.

Several analysts recently weighed in on the stock. Piper Sandler cut their price objective on shares of PROCEPT BioRobotics from $35.00 to $25.00 and set an “overweight” rating on the stock in a research report on Wednesday. Evercore set a $23.00 target price on shares of PROCEPT BioRobotics in a research report on Wednesday. Jefferies Financial Group restated a “hold” rating and issued a $20.00 price target on shares of PROCEPT BioRobotics in a research note on Wednesday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of PROCEPT BioRobotics in a report on Friday, July 17th. Finally, Leerink Partners downgraded PROCEPT BioRobotics from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $31.00 to $29.00 in a research report on Thursday, June 11th.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in PRCT. AQR Capital Management LLC increased its holdings in shares of PROCEPT BioRobotics by 7.3% during the first quarter. AQR Capital Management LLC now owns 18,892 shares of the company’s stock valued at $1,101,000 after purchasing an additional 1,286 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in PROCEPT BioRobotics by 9.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 153,158 shares of the company’s stock worth $8,923,000 after purchasing an additional 13,767 shares during the period. Intech Investment Management LLC lifted its holdings in PROCEPT BioRobotics by 54.4% in the first quarter. Intech Investment Management LLC now owns 28,389 shares of the company’s stock worth $1,654,000 after purchasing an additional 10,002 shares during the period. Prudential Financial Inc. grew its position in PROCEPT BioRobotics by 100.4% in the 2nd quarter. Prudential Financial Inc. now owns 6,815 shares of the company’s stock valued at $393,000 after buying an additional 3,415 shares in the last quarter. Finally, State Street Corp grew its position in PROCEPT BioRobotics by 6.9% in the 2nd quarter. State Street Corp now owns 1,269,110 shares of the company’s stock valued at $73,101,000 after buying an additional 81,849 shares in the last quarter. Institutional investors and hedge funds own 89.46% of the company’s stock.

PROCEPT BioRobotics Price Performance

Shares of NASDAQ PRCT opened at $20.41 on Friday. PROCEPT BioRobotics has a 1-year low of $16.67 and a 1-year high of $42.71. The company has a debt-to-equity ratio of 0.15, a current ratio of 6.55 and a quick ratio of 5.51. The business’s fifty day moving average price is $21.59 and its two-hundred day moving average price is $24.79. The firm has a market capitalization of $1.16 billion, a PE ratio of -10.52 and a beta of 0.89.

PROCEPT BioRobotics (NASDAQ:PRCT) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($0.01). The firm had revenue of $94.50 million for the quarter, compared to analyst estimates of $92.77 million. PROCEPT BioRobotics had a negative net margin of 32.53% and a negative return on equity of 30.62%. The business’s revenue was up 19.3% compared to the same quarter last year. During the same period last year, the firm posted ($0.35) EPS. On average, research analysts expect that PROCEPT BioRobotics will post -1.62 EPS for the current year.

Key PROCEPT BioRobotics News

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Positive Sentiment: PROCEPT reported quarterly revenue of $94.5 million, ahead of the $92.8 million consensus estimate, with year-over-year growth of 19.3%. The revenue beat helped support the shares despite a modest earnings miss. PROCEPT gains after Q2 beat; Wells Fargo downgrades
• Neutral Sentiment: PROCEPT posted an adjusted loss of $0.47 per share, narrowly worse than the $0.46 consensus estimate. The company remains unprofitable, and analysts expect a full-year loss of approximately $1.53 per share.
• Negative Sentiment: Wells Fargo downgraded PROCEPT to Equal Weight, adding pressure after the earnings report and signaling limited near-term upside in the firm’s view. Wells Fargo downgrades PROCEPT BioRobotics to Equal Weight
• Negative Sentiment: Multiple law firms publicized a securities-fraud class action covering investors who purchased PRCT shares from February 28, 2024 through February 25, 2026. The allegations concern weaker-than-expected handpiece sales and excess customer inventory allegedly created by late-quarter bulk discounts. The reports reference an approximately 18% stock decline and larger losses from the class-period high. The allegations have not been proven. PROCEPT securities fraud class action
• Negative Sentiment: Investors have been notified that September 22, 2026 is the lead-plaintiff deadline, increasing visibility around potential litigation costs, disclosure concerns and reputational risk. PROCEPT shareholder alert and lead plaintiff deadline

About PROCEPT BioRobotics

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.